Company Arcus Biosciences, Inc.

Equities

RCUS

US03969F1093

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 14:32:59 10/09/2024 BST			5-day change	1st Jan Change
16.26 ^USD	-0.28%		-4.73%	-14.61%

09-04	Transcript : Arcus Biosciences, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 04:50 PM
08-27	Arcus Biosciences Gets Up to $250 Million Term Loan Facility From Hercules Capital	MT

Business description: Arcus Biosciences, Inc.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Number of employees: 577

Sales by Activity: Arcus Biosciences, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023
Developing and Commercializing Immunotherapies	15M	77.52M	383M	112M	117M

See all business segments

Geographical breakdown of sales: Arcus Biosciences, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023
United States	15M	77.52M	383M	112M	117M

See all geographic segments

Managers: Arcus Biosciences, Inc.

Director	Title	Age	Since
Juan Jaen FOU	Founder	66	31/12/14
Terry Rosen CEO	Chief Executive Officer	65	31/12/14
Robert Goeltz DFI	Director of Finance/CFO	51	31/07/20
Dimitry Nuyten CTO	Chief Tech/Sci/R&D Officer	48	31/07/22
Jonathan Yingling CTO	Chief Tech/Sci/R&D Officer	55	31/12/19

See ARCUS BIOSCIENCES, INC. governance

Members of the board: Arcus Biosciences, Inc.

Manager	Title	Age	Since
Terry Rosen CEO	Chief Executive Officer	65	31/12/14
Kathryn Falberg BRD	Director/Board Member	63	17/09/17
Yasunori Kaneko BRD	Director/Board Member	70	30/04/15
Antoni Ribas BRD	Director/Board Member	58	27/10/19
Clarence Machado BRD	Director/Board Member	60	09/12/19
David Lacey BRD	Director/Board Member	71	20/05/20
Merdad Parsey BRD	Director/Board Member	61	12/07/20
Andrew Perlman BRD	Director/Board Member	76	16/12/20
Nicole Lambert BRD	Director/Board Member	50	02/08/21
Linda Higgins BRD	Director/Board Member	62	09/08/21

Composition of the Board of Directors

Shareholders: Arcus Biosciences, Inc.

Name	Equities	%	Valuation
GILEAD SCIENCES, INC. 34.49 %	31,532,781	34.49 %	540 M $
BlackRock Advisors LLC 10.16 %	9,289,480	10.16 %	159 M $
Vanguard Fiduciary Trust Co. 5.750 %	5,257,326	5.750 %	90 M $
Woodline Partners LP 4.643 %	4,245,221	4.643 %	73 M $
Fidelity Management & Research Co. LLC 4.573 %	4,180,791	4.573 %	72 M $

List of ARCUS BIOSCIENCES, INC. shareholders

Company details: Arcus Biosciences, Inc.

Arcus Biosciences, Inc.

3928 Point Eden Way

94545, Hayward

http://www.arcusbio.com

Other Biotechnology & Medical Research

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
ARCUS BIOSCIENCES, INC.	-0.28%	-4.73%	-23.71%	-52.63%	1.49B
LONZA GROUP AG	+0.50%	+0.70%	+12.23%	-28.75%	46.26B
IQVIA HOLDINGS INC.	-0.90%	-4.25%	+12.80%	-7.81%	43.91B
ALNYLAM PHARMACEUTICALS, INC.	+0.30%	-3.63%	+25.68%	+33.52%	32.5B
CELLTRION, INC.	+0.47%	-2.54%	+30.24%	-24.25%	29.51B
MODERNA, INC.	-0.31%	-1.02%	-28.83%	-83.20%	29.45B
ICON PUBLIC LIMITED COMPANY	+0.08%	-7.25%	+19.42%	+15.35%	24.74B
UNITED THERAPEUTICS CORPORATION	-0.70%	-4.08%	+54.89%	+65.35%	15.51B
BIO-TECHNE CORPORATION	-0.78%	-2.57%	+0.38%	-43.26%	11.43B
MEDPACE HOLDINGS, INC.	+0.81%	-4.47%	+25.18%	+75.67%	10.5B
Average	-0.05%	-3.55%	+12.83%	-5.00%	24.53B
Weighted average by Cap.	-0.01%	-3.19%	+14.56%	-8.70%